ArticleOrganic process research & development2026
Scalable Flow Synthesis of Genetically Encodable Tetrazine Amino Acids.
Article in Organic process research & development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The tetrazine-cyclooctene ligation is among the fastest bioorthogonal reactions known, enabling rapid and selective bioconjugation. Site-specific incorporation of tetrazine-bearing noncanonical amino acids (Tet-ncAAs) into proteins via genetic code expansion has expanded the toolkit for applications in chemical biology, therapeutic conjugation, and live-cell imaging. However, existing synthetic routes to Tet-ncAAs rely on small-scale batch reactions that rely on hazardous reagents and are poorly suited for scale-up. Here, we report both a hybrid batch-flow and continuous flow synthetic approaches for Tet-ncAAs that improve process safety, scalability, and reproducibility. The use of aqueous hydrazine in place of anhydrous hydrazine, 3-mercaptopropionic acid as an organic catalyst in place of metal salts, and a compatible solvent system enables the synthesis under safer, milder, and environmentally-friendly conditions. Optimization of the temperature for the reaction revealed a two-step process involving rapid hydrazine addition followed by cyclization at a lower temperature. This modular process supports multigram-scale synthesis of diverse Tet-ncAAs from commercial precursors and integrates a fully continuous oxidation protocol to access the final tetrazine products. The resulting platform offers a safer, scalable, and sustainable route to Tet-ncAAs that supports the growing demand in antibody-drug conjugates, radioimmunoconjugates, antibody-oligonucleotide and protein-protein conjugates as well as protein labeling and targeted delivery applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.